Keros Therapeutics (NASDAQ:KROS - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($1.13) per share and revenue of $3.83 million for the quarter.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. The business had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. During the same period in the prior year, the business earned ($1.21) earnings per share. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Keros Therapeutics Stock Performance
Shares of NASDAQ:KROS remained flat at $14.32 on Friday. The stock had a trading volume of 261,048 shares, compared to its average volume of 448,280. The firm has a market capitalization of $581.68 million, a P/E ratio of -79.56, a PEG ratio of 2.59 and a beta of 1.33. The business has a 50-day moving average of $14.05 and a 200 day moving average of $12.69. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.
Analyst Ratings Changes
Several equities analysts recently commented on KROS shares. Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the company from $32.00 to $18.00 in a research note on Tuesday, June 10th. Scotiabank lowered their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. HC Wainwright lowered their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wedbush reissued a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, Truist Financial reduced their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $30.56.
Read Our Latest Report on KROS
Institutional Trading of Keros Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Keros Therapeutics during the 1st quarter valued at $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Keros Therapeutics by 15.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company's stock worth $227,000 after acquiring an additional 2,982 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Stories

Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.